| Phase 4 |
| NCT07264894 |
ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a… |
Zhengzhou University |
Not Yet Recruiting |
2025-12-04 |
| Phase 3 |
| NCT06742996 |
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared… |
BeOne Medicines |
Recruiting |
2026-09-14 |
| NCT05976763 |
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for… |
Alliance for Clinical Trials in Oncology |
Recruiting |
2026-09-02 |
| NCT01804686 |
A Long-term Extension Study of PCI-32765 (Ibrutinib) |
Janssen Research & Development, LLC |
Recruiting |
2026-07-31 |
| NCT07377578 |
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With… |
Guangzhou Lupeng Pharmaceutical Company LTD. |
Recruiting |
2026-02-06 |
| NCT06363994 |
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL |
InnoCare Pharma Inc. |
Recruiting |
2024-12-27 |
| NCT06496308 |
Bendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment |
Ruijin Hospital |
Recruiting |
2024-07-11 |
| NCT03267433 |
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual… |
ECOG-ACRIN Cancer Research Group |
Active, Not Recruiting |
2026-09-14 |
| NCT07784101 |
A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib… |
Beijing InnoCare Pharma Tech Co., Ltd. |
Not Yet Recruiting |
2026-08-25 |
| NCT02972840 |
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously… |
Acerta Pharma BV |
Active, Not Recruiting |
2026-06-01 |
| NCT04002297 |
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With… |
BeOne Medicines |
Active, Not Recruiting |
2026-05-18 |
| NCT04662255 |
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With… |
Loxo Oncology, Inc. |
Active, Not Recruiting |
2026-05-15 |
| Phase 2 |
| NCT07003295 |
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type… |
National Cancer Institute (NCI) |
Recruiting |
2026-09-09 |
| NCT07029737 |
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for… |
AstraZeneca |
Recruiting |
2026-09-01 |
| NCT07341191 |
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma… |
Canadian Cancer Trials Group |
Recruiting |
2026-08-26 |
| NCT07673367 |
Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma |
Vanderbilt-Ingram Cancer Center |
Recruiting |
2026-08-17 |
| NCT07285044 |
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home… |
Mayo Clinic |
Recruiting |
2026-07-30 |
| NCT07272499 |
Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With… |
Ruijin Hospital |
Recruiting |
2026-07-28 |
| NCT06252675 |
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma |
University of California, San Francisco |
Recruiting |
2026-07-24 |
| NCT07082686 |
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or… |
Beijing InnoCare Pharma Tech Co., Ltd. |
Recruiting |
2026-07-23 |
| NCT07719556 |
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With… |
The First Affiliated Hospital with Nanjing Medical University |
Recruiting |
2026-07-22 |
| NCT04792489 |
DALY II USA/ MB-CART2019.1 for DLBCL |
Miltenyi Biomedicine GmbH |
Recruiting |
2026-07-13 |
| NCT06558604 |
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell… |
The Lymphoma Academic Research Organisation |
Recruiting |
2026-07-10 |
| NCT03314974 |
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders |
Masonic Cancer Center, University of Minnesota |
Recruiting |
2026-06-25 |
| NCT07453095 |
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following… |
Fondazione Italiana Linfomi - ETS |
Recruiting |
2026-06-25 |